Back to top
more

The Advisory Board Company (ABCO)

(Delayed Data from NSDQ)

$53.83 USD

53.83
895,134

+0.05 (0.09%)

Updated Nov 17, 2017 03:59 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

UnitedHealth (UNH) Scales a 52-Week High on Recent Deals

by Zacks Equity Research

UnitedHealth's (UNH) shares are riding on its recent acquisition announcements.

    UnitedHealth to Buy Advisory Board's Health Care Business

    by Zacks Equity Research

    The acquisition of Advisory Board's health care business will bolster UnitedHealth's (UNH) health management business.

      Humana (HUM) Hits 52-Week High on Solid Q2, Raised Outlook

      by Zacks Equity Research

      Humana's (HUM) shares have been favored by its strong earnings performance, guidance raise and completion of accelerated share buyback.

        Advisory Board (ABCO) in Focus: Stock Moves 6.4% Higher

        by Zacks Equity Research

        Advisory Board (ABCO) shares rose more than 6% in the last trading session, amid huge volumes.

          Advisory Board (ABCO) in Focus: Stock Moves 5.4% Higher

          by Zacks Equity Research

          Advisory Board (ABCO) was a big mover last session, as the company saw its shares rise over 5% on the day.

            Allergan's Restasis Now Available in Multidose Bottle in U.S.

            by Zacks Equity Research

            Allergan plc (AGN) recently announced that its marketed drug Restasis (cyclosporine ophthalmic emulsion) 0.05% is now available in multidose bottles in the U.S.

              Ultragenyx's Seizure Candidate UX007 Fails in Phase II Study

              by Zacks Equity Research

              Ultragenyx Pharmaceutical Inc. (RARE) recently announced that its pipeline candidate UX007 (triheptanoin) failed to meet the primary endpoint in a phase II study evaluating it for the treatment of patients with Glut1 DS with seizures.

                Array BioPharma's NDA for Cancer Drug Withdrawn; Shares Down

                by Zacks Equity Research

                Shares of Array BioPharma Inc. (ARRY) slipped 2.30% after the company announced that it has withdrawn its new drug application (NDA) for its pipeline candidate, binimetinib, from the FDA's Division of Oncology Products 2.

                  Jazz Sleep Disorder Drug Positive in Phase III Studies

                  by Zacks Equity Research

                  Jazz Pharmaceuticals plc (JAZZ) recently announced positive efficacy results from two phase III studies evaluating the safety and efficacy of its lead pipeline candidate JZP-110 for the treatment of excessive sleepiness.

                    BioDelivery (BDSI) Q4 Loss Wider Than Expected; Sales Meet

                    by Zacks Equity Research

                    BioDelivery Sciences International, Inc. (BDSI) reported loss of 29 cents per share in the fourth quarter of 2016, slightly wider than the Zacks Consensus Estimate of a loss of 28 cents.

                      Teva Launches Authorized Generic of Allergan's Minastrin

                      by Zacks Equity Research

                      Teva Pharmaceutical Industries Ltd. (TEVA) recently launched an authorized generic version of Allergan plc???s (AGN) oral contraceptive, Minastrin 24 Fe1, in the U.S.

                        Jazz Initiates Phase III Study for Narcolepsy Candidate

                        by Zacks Equity Research

                        Jazz Pharmaceuticals plc (JAZZ) recently announced the initiation of patient enrollment in a phase III study evaluating the efficacy and safety of its pipeline candidate, JZP-258, for the potential treatment of adult narcolepsy patients.

                          AstraZeneca's Cancer Drug Lynparza Positive in Phase III

                          by Zacks Equity Research

                          AstraZeneca plc (AZN) announced positive results from phase III SOLO-2 study which support the potential benefit of marketed drug Lynparza (olaparib) as a maintenance therapy in relapsed ovarian cancer.

                            Arena Pharmaceuticals (ARNA) Posts Q4 Earnings, Revenues Up

                            by Zacks Equity Research

                            Arena Pharmaceuticals, Inc. (ARNA) reported earnings of 16 cents per share in the fourth quarter of 2016, as against the year-ago loss of 13 cents and the Zacks Consensus Estimate of a loss of 9 cents.

                              Community Health Continues Divestiture, to Sell 4 Hospitals

                              by Zacks Equity Research

                              In its bid to divest units to lower its debt level, Community Health Systems, Inc. (CYH) has struck an agreement with PinnacleHealth System to sell four Pennsylvania hospitals and their associated assets.

                                Teladoc Continues to Grow in Booming Telehealth Industry

                                by Zacks Equity Research

                                Teladoc Inc. (TDOC), a premier telehealth services provider, is rapidly expanding its business in the booming telehealth services industry.

                                  Advisory Board Company (ABCO) Enters Overbought Territory

                                  by Zacks Equity Research

                                  The Advisory Board Company (ABCO) has moved higher as of late, but there could definitely be trouble on the horizon for this company.

                                    The Advisory Board (ABCO) in Focus: Stock Surges 16.2%

                                    by Zacks Equity Research

                                    The Advisory Board Company (ABCO) was a big mover last session, as the company saw its shares surged over 16% on the day.